Multiple Myeloma Non-Hodgkin Lymphoma CLL AML ALL Other Topics
Online Exclusive
COVID-19 & Multiple Myeloma: Delay ASCT
With the COVID-19 pandemic sweeping the world, The American Society for Transplant and Cellular Therapy (ASTCT) issued an interim guidance recommending delay of elective stem cell harvest and autologous and allogeneic transplants for multiple myeloma patients.
FDA Alert
FDA Approves Isatuximab-Irfc for Multiple Myeloma
The FDA approved isatuximab-irfc in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Your Career Path
Finding Your Mentorship Style
A successful mentor can lead their mentee to new heights of success, impart insider knowledge, be a guide in times of struggle and stress, and help the mentee conquer personal shortcomings. But how does one achieve a masterful level of mentorship?
Spotlight on Lymphomas
Selective HDAC3 Inhibition Found in Non-Hodgkin Lymphomas
By Richard Simoneaux
HDAC inhibitors have been approved by the FDA as monotherapies or in combinations for the treatment of a number of hematologic malignancies. Currently, preclinical research involving a selective HDAC3 inhibitor, BRD3308, is being conducted by a team headed up by Michael R. Green, PhD and Ari Melnick, MD.
Growing Treatment Options for Follicular LymphomaBy Rebecca WilsonFollicular lymphoma boasts a particularly robust armamentarium of treatment options. Clinicians can tailor a management strategy using everything from watchful waiting to involved-site radiation therapy (ISRT), single-agent and combination chemotherapy regimens, monoclonal antibody (MAB) therapy, radioimmunotherapy, and chemoimmunotherapy.
By Richard Simoneaux
The ROR1-targeting monoclonal antibody cirmtuzumab is currently being evaluated in a clinical setting among patients with a variety of malignancies. One particularly interesting clinical study is a phase I/II trial (NCT03088878) that is evaluating the combination of the Bruton's tyrosine kinase inhibitor ibrutinib plus cirmtuzumab in patients with CLL/SLL or MCL. (Abstract LBA3).
From the Issue
"We have made great strides in pediatric oncology therapy through cooperative group clinical trials. Currently, the overall cure rate for pediatric cancer is approximately 80 percent," noted Douglas Graham, PhD, Chief of the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta.
Colleague Conversations
Physician Burnout: Discussing Sources & Solutions
Hem/Onc Times sat down with Jonathan Fish, MD, and Adit Tal, MD, to discuss why there are increasing rates of physician burnout, how burnout affects patient treatment, and how the medical community should address this problem.
